Zai Lab (ZLAB) and Its Peers HeadHead Contrast

Zai Lab (NASDAQ: ZLAB) is one of 489 public companies in the “Pharmaceutical preparations” industry, but how does it compare to its rivals? We will compare Zai Lab to related companies based on the strength of its institutional ownership, dividends, risk, valuation, analyst recommendations, profitability and earnings.

Earnings & Valuation

Get Zai Lab alerts:

This table compares Zai Lab and its rivals revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Zai Lab N/A -$50.38 million -8.64
Zai Lab Competitors $2.01 billion $135.23 million -3.60

Zai Lab’s rivals have higher revenue and earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

20.5% of Zai Lab shares are owned by institutional investors. Comparatively, 46.3% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 15.8% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Zai Lab and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Zai Lab N/A N/A N/A
Zai Lab Competitors -2,959.10% -119.74% -30.63%

Analyst Recommendations

This is a breakdown of current ratings and target prices for Zai Lab and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zai Lab 0 0 3 0 3.00
Zai Lab Competitors 2978 9032 21951 619 2.58

Zai Lab currently has a consensus target price of $37.00, suggesting a potential upside of 84.63%. As a group, “Pharmaceutical preparations” companies have a potential upside of 38.65%. Given Zai Lab’s stronger consensus rating and higher probable upside, research analysts clearly believe Zai Lab is more favorable than its rivals.

Summary

Zai Lab beats its rivals on 6 of the 11 factors compared.

About Zai Lab

Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics for oncology, and autoimmune and infectious disease therapies in China. Its drug candidates include ZL-2306, a poly ADP ribose polymerase 1/2 inhibitor for the treatment of ovarian, breast, and lung cancers; ZL-2401, an antibiotic for the treatment of acute bacterial skin/skin structure infections, community-acquired bacterial pneumonias, and urinary tract infections; ZL-2301 that is Phase II clinical trial for the treatment of hepatocellular carcinoma; ZL-3101, a novel steroid-sparing topical product that is in Phase II clinical trial for the treatment of eczema and psoriasis; ZL-2302 for the treatment of non-small cell lung cancer; and ZL-1101, an anti-OX40 antagonistic antibody for the treatment of graft-versus-host disease or systemic lupus erythematosus. The company was founded in 2013 and is headquartered in Shanghai, China.